Study details
Enrolling now
A Phase 1 Trial of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
NCT IDNCT06515613ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
80
Study length
about 3.8 years
Ages
18+
Locations
13 sites in AR, CA, CO +10
What this study is about
Researchers are testing a new treatment called CTIM-76 to see if it's safe and effective for people with recurring ovarian cancer or other advanced solid tumors. The trial will involve giving CTIM-76 to adults who have not responded well to platinum-based treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CTIM-76
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of Dose Limiting Toxicities (DLTs), Overall response rate (ORR)
Body systems
Oncology